Novo Nordisk A/S Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people with overweight or obesity was published in The Lancet and presented at the ...

While the broader market hesitated, the recently listed bull stock Circle continued to hit new highs on Friday, surging 20% to reach a share price of $240 (IPO price was $31), marking an increase of ...

Type two diabetes is on the rise globally, primarily caused by insulin resistance believed to be connected to lifestyle ...

Managing your body weight and BMI could be the key to keeping your type two diabetes risk down, according to a new study ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Weight-loss surgery significantly reduces the risk of psychiatric issues like cognitive decline, anxiety, and substance use ...

Obesity caused by a high-fat Western diet damages the pancreas, affecting insulin production and blood sugar control even ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announc ...

Machine learning models can accurately predict which babies are at risk of being born with low birth weight, enabling earlier ...

The American College of Cardiology has issued new guidelines recommending weight management medications as first-line ...